Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-Analysis

    April 2015 in “ Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ”
    Abraham Zlotogorski, Yuval Ramot
    Image of study
    TLDR The safety of the hair loss drug finasteride is unclear due to inadequate reporting in clinical trials.
    In 2015, Belknap et al. conducted a meta-analysis of 34 clinical trials to evaluate the safety reporting in published clinical trials of finasteride, an FDA-approved oral drug for androgenetic alopecia (AGA). They found that none of the trials had adequate safety reporting, with only 19 having partially adequate reporting. Major flaws included lack of assessment of adequacy of blinding and lack of generalizability. The study concluded that there was insufficient information to determine the exact safety profile for finasteride, despite its common use and general perception as a safe treatment modality for AGA. This conclusion was deemed crucial for dermatologists when discussing the benefit to risk ratio with their patients seeking advice for treating AGA.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 1000+ results

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

      in Research/Science  136 upvotes 7 months ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

      community Anyone else growing tired of the finasteride wars?

      in Finasteride/Dutasteride  169 upvotes 1 year ago
      The conversation is about differing experiences with finasteride for hair loss, with some users reporting side effects and others not, and the debate over the drug's safety and effectiveness. Specific treatments mentioned include finasteride, dutasteride, and topical finasteride.

      community Maintaining hair until Breezula without Fin

      in Treatment  6 upvotes 4 years ago
      A 21-year-old male experienced side effects from topical finasteride and is seeking alternative treatments to maintain hair until Breezula is available. He is considering using minoxidil, Nizoral, micro-needling, and vitamin D supplementation, and may try CB or RU58841 if necessary.

      community Why is everyone not directly advised Dutasteride?

      in Finasteride/Dutasteride  165 upvotes 1 month ago
      Dutasteride is less commonly prescribed for hair loss because it is not FDA-approved for this purpose, unlike finasteride, which is more accessible and preferred due to fewer side effects. Dutasteride may be more effective in reducing DHT but has a longer half-life and potentially more significant side effects.

      community Received Kintor’s KX-826 Today

      in Product  84 upvotes 3 months ago
      A user received Kintor’s KX-826/Pyrilutamide and shared initial impressions, noting concerns about the product's labeling and marketing. Other users discussed the legitimacy of the product, its effectiveness, and compared it to other treatments like Minoxidil and Finasteride.

    Related Research

    1 / 1 results